| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/15/2011 | EP2332934A1 Chrystals including a malic acid salt of N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof |
| 06/15/2011 | EP2332933A1 Epithelial sodium channel (ENaC) inhibitors |
| 06/15/2011 | EP2332932A1 Novel crystal forms of 4-(2-aminopyridin-4-yl)-3-(4 fluoro- phenyl)-1-(1,4,5,6-tetrahydro-6-oxopyridazin-3-yl)-1h-pyra-zole methanesulfonate and process for production of same |
| 06/15/2011 | EP2332930A1 Salts of duloxetine and NSAIDs for the treatment of pain |
| 06/15/2011 | EP2332929A1 Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions |
| 06/15/2011 | EP2332925A1 Novel dihydrotriazine derivative |
| 06/15/2011 | EP2332924A1 Pyrimidine derivates, medicaments comprising them, their use and process of their preparation |
| 06/15/2011 | EP2332922A1 N-substituted azoles and their use as MEK-1 and/or ERK-2 modulators |
| 06/15/2011 | EP2332921A1 Processes for the Separation of 3-Benzazepine Racemates |
| 06/15/2011 | EP2332920A2 Processes for preparing 3-benzazepines |
| 06/15/2011 | EP2332919A2 Processes for preparing 3-benzazepines |
| 06/15/2011 | EP2332917A1 Compounds for PIM kinase inhibition and for treating malignancy |
| 06/15/2011 | EP2332915A1 Beta2-adrenoceptor agonists |
| 06/15/2011 | EP2332912A1 Heteroarylaminosulfonylphenylderivates for use as sodium or calcium channel blockers in the treatment of pain |
| 06/15/2011 | EP2332910A1 New derivatives of azabicyclo[3.2.0]hept-3-yl, method for preparing same and pharmaceutical compositions containing them |
| 06/15/2011 | EP2332909A1 Hydroxybenzamide derivatives and their use as inhibitors of HSP90 |
| 06/15/2011 | EP2332904A2 Derivatives of tetracycline compounds |
| 06/15/2011 | EP2332580A1 A composition for the treatment of the central nervous system |
| 06/15/2011 | EP2332574A1 HCV NS3/4A Sequences |
| 06/15/2011 | EP2332572A1 Nucleic acid vaccines for prevention of Flavivirus |
| 06/15/2011 | EP2332568A1 Collagenase for opening obstructed biological conduits |
| 06/15/2011 | EP2332561A1 Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| 06/15/2011 | EP2332556A1 Use of yeasts for treating stomach or intestinal ulcers induced by gastrotoxic agents |
| 06/15/2011 | EP2332553A1 Methods and compositions to treat myocardial conditions |
| 06/15/2011 | EP2332552A2 Composition for prevention or treatment of hyperlipidemia, fatty liver or obesity |
| 06/15/2011 | EP2332551A1 Use of thioarabinofuranosyl compounds |
| 06/15/2011 | EP2332550A1 Tetracyclines for the treatment of neurodegenerative diseases |
| 06/15/2011 | EP2332549A1 Novel tetracyclines and their use in medicine |
| 06/15/2011 | EP2332548A1 Tetracyclines for the treatment of stroke |
| 06/15/2011 | EP2332547A1 Tetracyclines for the treatment of inflammatory bowel disease |
| 06/15/2011 | EP2332546A1 Tetracyclines for the treatment of stroke |
| 06/15/2011 | EP2332545A1 Composition for treating central nervous system disorders |
| 06/15/2011 | EP2332544A1 New pharmaceutical composition suitable for treating persons affected by human immunodeficiency virus (HIV) |
| 06/15/2011 | EP2332543A1 Tetrahydrobenzazepines and their use in the modulation of the dopamine D3 receptor |
| 06/15/2011 | EP2332542A2 Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors |
| 06/15/2011 | EP2332541A1 Use of thioxanthine derivatives as MPO inhibitors |
| 06/15/2011 | EP2332540A1 Administration of ranolazine for the treatment of diabetes |
| 06/15/2011 | EP2332539A1 Pharmaceutical preparation, food or beverage having inhibitory activity on serotonin transporter |
| 06/15/2011 | EP2332538A1 Combinations comprising a 4-isoquinolone derivative and anti-HIV agents |
| 06/15/2011 | EP2332537A1 Combinations of nicotinic acetylcholine alpha 7 receptor agonists |
| 06/15/2011 | EP2332536A1 Inhibitors of protein tyrosine kinase activity |
| 06/15/2011 | EP2332535A1 Solid pharmaceutical composition |
| 06/15/2011 | EP2332534A1 Phenol and benzoquinone derivatives for use in the treatment of mitochondrial diseases and modulation of energy biomarkers |
| 06/15/2011 | EP2332533A1 Cannabinoid-containing plant extracts as neuroprotective agents |
| 06/15/2011 | EP2332532A1 New multi-therapy administration patterns suitable for treating persons affected by human immunodeficiency virus (HIV) |
| 06/15/2011 | EP2332531A1 Apo2 ligand/TRAIL formulations |
| 06/15/2011 | EP2332530A1 The use of potassium 2-( - hydroxypentyl) benzoate in the manufacture of medicaments for preventing and/or treating senile dementia |
| 06/15/2011 | EP2332529A1 Substituted aromatic diamines as ligands of vesicular glutamate transporter 1 and 2 (vGLUT1 and vGLUT2) |
| 06/15/2011 | EP2332528A1 Substituted aromatic dicarbonic acid amides as medicaments |
| 06/15/2011 | EP2332527A2 Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases |
| 06/15/2011 | EP2332526A2 Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
| 06/15/2011 | EP2332525A1 Pharmaceutical composition comprising propofol |
| 06/15/2011 | EP2332523A1 Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| 06/15/2011 | EP2332522A2 Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
| 06/15/2011 | EP2332427A1 low caloric fat replacers |
| 06/15/2011 | EP2332414A2 Crystallization of polyol compositions, crystalline polyol composition product and use thereof |
| 06/15/2011 | EP2332410A1 Process for preparing oxymorphone, naltrexone, and buprenorphine |
| 06/15/2011 | EP2332409A1 Process for preparing oxymorphone, naltrexone and buprenorphine |
| 06/15/2011 | EP2331967A2 New method for identifying compounds useful for treating and/or preventing diseases associated with bone loss |
| 06/15/2011 | EP2331581A1 Carboxyethylated cyclodextrin polysulfates useful as medicaments |
| 06/15/2011 | EP2331571A1 Nmda receptor modulators and uses thereof |
| 06/15/2011 | EP2331554A1 Macrocyclic indole derivatives useful as hepatitis c virus inhibitors |
| 06/15/2011 | EP2331552A1 Hepatitis c virus inhibitors |
| 06/15/2011 | EP2331551A1 Thienopyrimidines for pharmaceutical compositions |
| 06/15/2011 | EP2331548A1 Protease inhibitors |
| 06/15/2011 | EP2331547A1 Pyrrolopyrimidine compounds as cdk inhibitors |
| 06/15/2011 | EP2331546A1 2-alkyl-6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-ib]-pyridazine derivatives, preparation thereof, and therapeutic application thereof |
| 06/15/2011 | EP2331544A1 2-amino pyrimidine compounds as potent hsp-90 inhibitors |
| 06/15/2011 | EP2331543A1 3-deazaneplanocin derivatives |
| 06/15/2011 | EP2331542A2 A3 adenosine receptor antagonists and partial agonists |
| 06/15/2011 | EP2331541A1 Indolizine inhibitors of leukotriene production |
| 06/15/2011 | EP2331539A2 1,3,4,6,7,11b-hexahydro-benzo[alpha]quinolizines for the treatment of hyperkinetic movement and related disorders |
| 06/15/2011 | EP2331538A1 Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent hcv inhibitor |
| 06/15/2011 | EP2331537A1 Organic compounds |
| 06/15/2011 | EP2331534A1 Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators |
| 06/15/2011 | EP2331530A2 Fused multicyclic compounds as protein kinase inhibitors |
| 06/15/2011 | EP2331529A2 Novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone and pharmaceutical compositions thereof |
| 06/15/2011 | EP2331528A2 Compounds for the treatment of inflammatory disorders |
| 06/15/2011 | EP2331527A1 Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators |
| 06/15/2011 | EP2331526A2 Pyrimidine derivatives as kinase inhibitors |
| 06/15/2011 | EP2331525A2 Halofuginone analogs for inhibition of trna synthetases and uses thereof |
| 06/15/2011 | EP2331523A1 Pyridine and pyrimidine based compounds as wnt signaling pathway inhibitors for the treatment of cancer |
| 06/15/2011 | EP2331522A2 Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof |
| 06/15/2011 | EP2331521A1 Therapeutic compounds |
| 06/15/2011 | EP2331520A1 Rosamine derivatives as agents for the treatment of cancer |
| 06/15/2011 | EP2331518A1 New bradykinin b1 antagonists |
| 06/15/2011 | EP2331516A1 Imine derivatives as cannabinoid receptor ligands |
| 06/15/2011 | EP2331511A1 Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| 06/15/2011 | EP2331506A1 Novel benzamides, production thereof, and use thereof as medicaments |
| 06/15/2011 | EP2331505A2 Piperidine-4-acetamide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 06/15/2011 | EP2331504A2 Piperidylpropionamide derivatives useful for the treatment of cns disorders including depression and panic disorder |
| 06/15/2011 | EP2331503A1 4-phenoxymethylpiperidines as modulators of gpr119 activity |
| 06/15/2011 | EP2331502A2 Compounds for the treatment of hepatitis c |
| 06/15/2011 | EP2331501A1 Small molecule inhibitors of n-terminus activation of the androgen receptor |
| 06/15/2011 | EP2331500A1 Pyrrolidine n-benzyl derivatives |
| 06/15/2011 | EP2331498A2 Cold menthol receptor antagonists |
| 06/15/2011 | EP2331497A1 Dendrimeric compounds comprising amino acids, hyperbranched core compound, process for preparation of dendrimeric compounds comprising amino acids and hyperbranched core compound, and use thereof |
| 06/15/2011 | EP2331496A1 Use of an n-acyl amino acid selected from among n-palmitoyl alanine, n-palmitoyl glycine, and n-palmitoyl isoleucine as a regulating active agent of the genetic profile of senescent replicating fibroblasts of the human skin dermis |
| 06/15/2011 | EP2331494A1 A process for the preparation of rotigotine |
| 06/15/2011 | EP2331210A2 Pharmaceutical combination of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an antiepileptic |